Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PTPRA | P18433 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10411105 | 0.77 | FDPS (0.51) | SMN1; SMN2FDPSCYP1A2CYP2C19PTPRA | |
| SCHEMBL333243 | 0.74 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP1A2CYP2C19PTPRAALDH1A1 | |
| SCHEMBL29499090 | 0.74 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP1A2CYP2C19PTPRAALDH1A1 | |
| SCHEMBL1697473 | 0.74 | BLM (0.48) | SMN1; SMN2ALDH1A1HPGDALOX15TDP1 | |
| Hydrochloric Acid SCHEMBL28672925 | 0.73 | SMN1; SMN2 (0.60) | SMN1; SMN2CYP1A2CYP2C19PTPRAALDH1A1 | |
| Hydrochloric Acid SCHEMBL4174816 | 0.73 | SMN1; SMN2 (0.60) | SMN1; SMN2CYP1A2CYP2C19PTPRAALDH1A1 | |
| SCHEMBL6638562 | 0.73 | FDPS (0.54) | SMN1; SMN2FDPSCYP1A2CYP2C19PTPRA | |
| SCHEMBL8735900 | 0.73 | SMN1; SMN2 (0.40) | SMN1; SMN2FDPSCYP1A2CYP2C19PTPRA | |
| SCHEMBL5052828 | 0.72 | FDPS (0.58) | SMN1; SMN2FDPSPTPRAALDH1A1ALOX15 | |
| SCHEMBL3673389 | 0.71 | SMN1; SMN2 (0.73) | SMN1; SMN2CYP1A2CYP2C19PTPRAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819359-B1 | ANTI-INTEGRIN IMMUNOCONJUGATES, METHODS OF THEIR PRODUCTION AND THEIR USE | JANSSEN BIOTECH INC (US) | 2015-03-18 | — | — | EP | claimed |
| EP-1819359-A2 | ANTI-INTEGRIN IMMUNOCONJUGATES, METHODS AND USES | Centocor, Inc. (US) | 2007-08-22 | — | — | EP | claimed |
| WO-2006062779-A2 | ANTI-INTEGRIN IMMUNOCONJUGATES, METHODS AND USES | CENTOCOR, INC. (US) | 2006-06-15 | — | — | WO | claimed |
| US-20060127407-A1 | Anti-integrin immunoconjugates, methods and uses | JANSSEN BIOTECH, INC. | 2006-06-15 | — | — | US | claimed |
| EP-1395290-A2 | CYTOTOXIC CD44 ANTIBODY IMMUNOCONJUGATES | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 2004-03-10 | — | — | EP | claimed |
| WO-2002094325-A2 | CYTOTOXIC CD44 ANTIBODY IMMUNOCONJUGATES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2002-11-28 | — | — | WO | claimed |
| US-7361347-B2 | Cytotoxic CD44 antibody immunoconjugates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-22 | — | — | US | disclosed |
| US-20050271672-A1 | Cytotoxic CD44 antibody immunoconjugates | ADOLF GUENTHER | 2005-12-08 | — | — | US | disclosed |
| EP-1395290-A2 | CYTOTOXIC CD44 ANTIBODY IMMUNOCONJUGATES | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 2004-03-10 | — | — | EP | disclosed |
| US-20030103985-A1 | Cytotoxic CD44 antibody immunoconjugates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-06-05 | — | — | US | disclosed |
| WO-2002094325-A2 | CYTOTOXIC CD44 ANTIBODY IMMUNOCONJUGATES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050271672-A1 | Cytotoxic CD44 antibody immunoconjugates | CD44, CD47, EPCAM | SMN1; SMN2 2871/4885FDPS 4326/4885CYP1A2 4491/4885 |
| US-20030103985-A1 | Cytotoxic CD44 antibody immunoconjugates | CD44, CD47, EPCAM | SMN1; SMN2 2871/4885FDPS 4326/4885CYP1A2 4491/4885 |
| US-20060127407-A1 | Anti-integrin immunoconjugates, methods and uses | ITGB3, ITGB5, ITGB4 | SMN1; SMN2 2872/4885FDPS 936/4885CYP1A2 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.